Merck, India's Sun Pharma Establish JV To Develop Novel Combinations Of Branded Drugs
This article was originally published in The Pink Sheet Daily
The companies will focus on innovative branded generic combination drugs, which improve compliance and convenience, to sell in emerging markets.
You may also be interested in...
MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar
Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)
During the recent Pharmaceutical Strategic Alliances Conference in New York, Pfizer's Emerging Markets Business Unit President Jean-Michel Halfon and Merck's Chief Strategy Officer and Emerging Markets R&D Senior VP Merv Turner discussed priorities in tackling emerging markets. In part one, the execs outlined the steps companies should take to set up operations in emerging markets and in this second part they share their experiences in building a presence in China.
MUMBAI - The fight for a share of India's growing diabetes drugs market is set to become more fierce as Novartis is exploring an alliance with USV for promoting its type 2 anti-diabetes drug brand Jalra (vildagliptin)